Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors

European Journal of Haematology

Volumn 75, Issue 4, 2005, Pages 299-308

  Kim, Dong Hwan ^a   Sohn, Sang Kyun ^a   Lee, Nan Young ^a   Baek, Jin Ho ^a   Kim, Jong Gwang ^a   Won, Dong I L ^a   Suh, Jang Soo ^a   Lee, Kyu Bo ^a   Shin, Im Hee ^b  

^a Kyungpook National University Hospital   (South Korea)

^b Catholic University of Daegu   (South Korea)

Author keywords

Allogeneic PBSCT; Natural killer cell; Non relapse mortality; Transplant cell dose

Indexed keywords

CD34 ANTIGEN; CD56 ANTIGEN; CYTOKINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; INFECTION; INFUSION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PRIORITY JOURNAL; SIBLING; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIGENS, CD34; CELL COUNT; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNE SYSTEM; INCIDENCE; INFECTION; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REGENERATION; RETROSPECTIVE STUDIES; SIBLINGS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 24744451399     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00514.x     Document Type: Article

References (33)

1. ZAUCHA JM, GOOLEY T, BENSINGER WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001;98:3221-3227.
2. MOHTY M, BILGER K, JOURDAN E, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003;17:869-875.
3. SOHN SK, KIM JG, KIM DH, LEE NY, SUH JS, LEE KB. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;31:967-972.
4. PEREZ-SIMON JA, DIEZ-CAMPELO M, MARTINO R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003;102:1108-1113.
5. YAMASAKI S, HENZAN H, OHNO Y, et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant 2003;32:505-510.
6. SOHN SK, KIM JG, SEO KW, CHAE YS, JUNG JT, SUH JS, LEE KB. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;30:81-86.
7. SOHN SK, KIM JG, CHAE YS, KIM DH, LEE NY, SUH JS, LEE KB. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 2003;18:10-15.
8. PRZEPIORKA D, WEISDORF D, MARTIN P, KLINGEMANN HG, BEATTY P, Hows J, THOMAS ED. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
9. SHULMAN HM, SULLIVAN KM, WEIDEN PL, MCDONALD GB, STRIKER GE, SALE GE, HACKMAN R, TSOI MS, STORB R, THOMAS ED. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
10. KIM JG, SOHN SK, KIM DH, LEE NY, SUH JS, LEE KS, LEE KB. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73:56-61.
11. RUGGERI L, CAPANNI M, CASUCCI M, VOLPI I, TOSTI A, PERRUCCIO K, URBANI E, NEGRIN RS, MARTELLI MF, VELARDI A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-339.
12. ASAI O, LONGO DL, TIAN ZG, HORNUNG RL, TAUB DD, RUSCETTI FW, MURPHY WJ. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998;101:1835-1842.
13. URBINI B, ARPINATI M, BONIFAZI F, et al. Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant. Exp Hematol 2003;31:959-965.
14. YANG ZG, ZENG YY, HE XH, WANG Q, JIANG X. Effect of natural killer cell on hematopoiesis and immunity recovery in mouse allogeneic bone marrow transplantation. Zhong-hua Xue Ye Xue Za Zhi 2004;25:713-716.
15. MORETTA L, FERLAZZO G, MINGARI MC, MELIOLI G, MORETTA A. Human natural killer cell function and their interactions with dendritic cells. Vaccine 2003;21(Suppl 2):S38-S42.
16. CHEN BJ, CUI X, SEMPOWSKI GD, DOMEN J, CHAO NJ. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 2004;103:4344-4352.
17. STOREK J, DAWSON MA, MALONEY DG. Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation. Biol Blood Marrow Transplant 2003;9:781-784.
18. CAO TM, SHIZURU JA, WONG RM, et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 2005;105:2300-2306.
19. GEROSA F, BALDANI-GUERRA B, NISII C, MARCHESINI V, CARRA G, TRINCHIERI G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-333.
20. NIEDERWIESER D, GASTL G, RUMPOLD H, MARTH C, KRAFT D, HUBER C. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol 1987;65:301-305.
21. TALMADGE JE, REED E, INO K, KESSINGER A, KUSZYNSKI C, HEIMANN D, VARNEY M, JACKSON J, VOSE JM, BIERMAN PJ. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997;19:161-172.
22. ROBERTS MM, To LB, GILLIS D, MUNDY J, RAWLING C, NG K, JUTTNER CA. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993;12:469-475.
23. ANDERSON KC, RITZ J, TAKVORIAN T, CORAL F, DALEY H, GORGONE BC, FREEDMAN AS, CANELLOS GP, SCHLOSSMAN SF, NADLER LM. Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood 1987;69:597-604.
24. REITTIE JE, GOTTLIEB D, HESLOP HE, LEGER O, DREXLER HG, HAZLEHURST G, HOFFBRAND AV, PRENTICE HG, BRENNER MK. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989;73:1351-1358.
25. POWLES R, SINGHAL S, TRELEAVEN J, KULKARNI S, HORTON C, MEHTA J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998;91:3481-3486.
26. KUMAR S, CHEN MG, GASTINEAU DA, GERTZ MA, INWARDS DJ, LACY MQ, TEFFERI A, LITZOW MR. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001;28:951-956.
27. KUMAR S, CHEN MG, GASTINEAU DA, GERTZ MA, INWARDS DJ, LACY MQ, TEFFERI A, LITZOW MR. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 2003;17:1865-1870.
28. JIANG YZ, BARRETT AJ, GOLDMAN JM, MAVROUDIS DA. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1997;74:1-6.
29. KIM DH, KIM JG, SOHN SK, SUNG WJ, SUH JS, LEE KS, LEE KB. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004;125:217-224.
30. RICHARD C, BARO J, BELLO-FERNANDEZ C, et al. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse. Bone Marrow Transplant 1995;15:721-726.
31. BURNS LJ, WEISDORF DJ, DEFOR TE, REPKA TL, OGLE KM, HUMMER C, MILLER JS. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp Hematol 2000;28:352.
32. VERBIK DJ, JACKSON JD, PIRRUCCELLO SJ, PATIL KD, KESSINGER A, JOSHI SS. Functional and phenotypic characterization of human peripheral blood stem cell harvests: a comparative analysis of cells from consecutive collections. Blood 1995;85:1964-1970.
33. RUGGERI L, CAPANNI M, URBANI E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.